Table 3.

Responses to alisertib

ResponderNonresponders
StratumResponse evaluableComplete responsePartial responseStable disease, n patients, median (range) cycles administeredNonrespondersProgressive disease
NBL (measurable)2412 (6, 13 cycles)516
NBL (MIBG evaluable)24119 [13 (5–35) cycles]49
ALL103 (1, 2, 2 cycles)16
AML1010
EWS103 (4, 5, 5 cycles)25
Rhabdo-myosarcoma101 (15 cycles)27
NR-STS101 (5 cycles)27
OS1028
Wilms tumor1011 (31 cycles)17
Hepatoblastoma81a1 (5 cycles)24
Germ cell tumor72 (4 and 5 cycles)14
Rhabdoid tumors413
Total13723233376
  • aReported previously in ADVL0812 publication (29).